Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls

Cancer

Volumn 98, Issue 10, 2003, Pages 2088-2090

  Syed, Samira ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANDROGEN; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; VINBLASTINE; WARFARIN;

ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BONE PAIN; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT; HUMAN; MALAISE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PATHOLOGIC FRACTURE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SOCIAL BEHAVIOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0242611601     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11788     Document Type: Review

References (12)

1. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 2002;20:31-35.
2. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
3. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
4. Osoba D, Tannock IF, Ernst S, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654-1663.
5. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
6. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005-2012.
7. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostrate cancer. J Clin Oncol. 1992;10:1754-1761.
8. Petrylak DP, Shelton GB, England-Owen C, et al. Response and preliminary survival results of a Phase II study of docetaxel (D) + estramustine (E) in patients (Pts) with androgen-independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol. 2000;19:334a.
9. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001;19:2509-2516.
10. Hudes GR, Nathan FE, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995;22:41-45.
11. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol. 1999;17:1664-1671.
12. Meluch AA, Greco FA, Morrissey LH, et al. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2003;98:2192-2198.